|
|
Monthly information regarding the total number of voting rights and
total number of shares of the Company as of June 30, 2023
Article 22316 of the General Regulations of the Autorité des Marchés Financiers
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
Date Total number of shares Total number of voting... Lire le communiqué |
|
| |
|
| |
|
|
Informations Réglementées
Montrouge, France, le 10 juillet 22 :30 CET 2023
Bilan semestriel du contrat de liquidité DBV
Technologies avec ODDO BHF
DBV Technologies Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT,
laboratoire biopharmaceutique français, publie aujourd’hui le bilan semestriel... Lire le communiqué |
|
| |
|
| |
|
|
r
AMF Regulated Information
Montrouge, France, July 10, 2023
HalfYear Report on the DBV Technologies Liquidity
Contract with ODDO BHF
DBV Technologies Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT, a clinicalstage biopharmaceutical company, today issued the... Lire le communiqué |
|
| |
|
| |
|
|
Information mensuelle relative au nombre total des droits de vote et
d’actions composant le capital social au 31 mai 2023
Article 22316 du Règlement Général de l’Autorité des Marchés Financiers
Place de cotation : NYSE Euronext Paris
Code ISIN : FR 0010417345
Nombre total
... Lire le communiqué |
|
| |
|
| |
|
|
Monthly information regarding the total number of voting rights and
total number of shares of the Company as of May 31, 2023
Article 22316 of the General Regulations of the Autorité des Marchés Financiers
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
Date Total number of shares Total number of voting... Lire le communiqué |
|
| |
|
| |
|
|
Montrouge, France, June 8, 2023
DBV Technologies to Participate in Upcoming EAACI
Congress 2023
DBV Technologies Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT, a clinicalstage biopharmaceutical company, today announced upcoming
participation in the European Academy of Allergy and Clinical Immunology EAACI
Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will... Lire le communiqué |
|
| |
|
| |
|
|
Montrouge, France, 8 juin 2023
DBV Technologies participera au prochain congrès
de l’EAACI 2023
DBV Technologies Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market :
DBVT, société biopharmaceutique au stade clinique, a annoncé aujourd’hui sa
participation au prochain congrès de l’European Academy of Allergy and Clinical
Immunology EAACI, qui se tiendra du 9 au 11 juin... Lire le communiqué |
|
| |
|
| |
